Epilepsy Patients are the New Focus of ChineseInvestors.com, Inc.’s (CIIX) CBD Health Products

In China, there are close to 10 million epilepsy patients, the Chinese Overseas Medical Advisory Service Center estimates. There is no cure in the country, although risky surgery is sometimes performed in the U.S., where there are over three million people living with epilepsy. Many patients rely on Chinese herbs for temporary control. However, ChineseInvestors.com’s (OTCQB: CIIX) current development plan includes making cannabidiol (CBD) products available online for people with epilepsy and Alzheimer’s disease. Its online store (ChineseCBDoil.com) and Yelp-style mobile application are helping to serve Chinese-speaking consumers around the world, and investors as well, with a reach into the $202 million U.S. CBD industry (based on 2015 consumer sales), which is expected to exceed $2 billion by 2020.

Cannabis was used as a medicinal substance in China as early as 2700 BCE, and it was later used across India and the Middle East. Epilepsy patients were treated with cannabis as early as the 11th century. This application was studied in Europe in the 19th century, and research into the medical use of cannabis compounds took place throughout the 1930s and 1940s. Progress was hindered in 1970 as the U.S. Controlled Substances Act prohibited the production and use of any cannabis product. Today, cannabis-based products are gaining ground, and CIIX is paying close attention to the market.

Read the full article

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer